Venture Capital & Emerging Companies

We know how to help you turn your ideas into reality. Our attorneys can provide you with legal services that evolve as your enterprise does — from start-up to successful exit. 

Because we work to understand your business, we’ll help examine your corporate requirements, intellectual property protection, employment issues, and regulatory and compliance needs, and assess how these impact your bottom line. That’s what we’ve already done for many major companies and investors in the information technology, digital media, social media, life sciences, health care, and energy and clean technology sectors.

We’re experienced in representing clients in all types of financings — from early- or seed-stage investments through later stages. We provide counsel to companies, investors, and financial advisors in a range of sophisticated transactions.

Quick Facts

  • Venture capital transactions with an aggregate deal value of over $2 billion since 2013
  • Represent venture capital firms and other private equity investors and venture capital-backed
  • Experience in all stages - from early- or seed-stage investments through subsequent multi-investor and late-stage financings, and IPOs
  • Frequently and successfully initiate introductions between our start-up clients and our network of angel investors and venture capital firms

Areas of Focus

  • Start-Up services
    • Incorporation
    • Intellectual property protection
    • Option plans
    • Proprietary information agreements
    • Restricted stock agreements
    • Stockholder agreements

  • Corporate transactions
    • Commercial contracts
    • International transactions
    • Joint ventures
    • Licensing
    • Mergers and acquisitions
    • Outsourcing agreements
    • Strategic alliances

  • Employee, labor, and benefits counseling
    • Compensation arrangements
    • Employee handbooks
    • Immigration
    • Noncompete protection

  • Financings
    • Alternative public offerings
    • Cross-border financings
    • Debt and equity structures
    • IPOs
    • Private placements
    • Seed stage and “angel” financings
    • Venture financings

  • Fund formation
    • Broker-dealer and investment advisor regulatory compliance
    • Investment advisory agreements
    • Limited liability company agreements
    • Limited partnership agreements
    • Private placement memoranda

  • Government relations
    • Federal government regulations
    • Lobbying

  • Intellectual property
    • Copyrights
    • Patents
    • Privacy and security
    • Technology transfer
    • Trademarks

  • Tax structuring and advice
    • Minimizing tax on equity grants
    • Structuring transactions

Sort by: Name  Title  Office

Representative Experience

  • Represented XL Hybrids, a transformative energy company focused on transportation, in its $10.5 million Series C financing led by an individual investor.
  • Represented Intercept Pharmaceuticals, Inc. in its $30 million Series C financing led by OrbiMed Advisors and Genextra.
  • Represented AccuVein, Inc. in its $7.1 million financing led by MVM Life Sciences Fund, Bessemer Venture Partners, Tullis, and Lynch Foundation.
  • Represented Tarsa Therapeutics, Inc. in its $28 million Series B financing led by Foresite Capital, Novo A/S, MVM Life Sciences Fund, and Quaker Partners.
  • Served as deal counsel to Soligent Holdings, LLC, the largest US provider of residential solar panels, in three acquisitions totaling over $100 million.
  • Represented Compass Labs, Inc. in its $6 million financing led by Presidio Ventures and NEA (New Enterprise Associates).
  • Represented Extole, Inc. in its $10.2 million financing led by Shasta Ventures, Trident Capital, Redpoint Ventures, and Norwest Venture Partners.
  • Represented Aspen Aerogels, a leading energy technology company providing innovative thermal management solutions, in its $82.5 million Initial Public Offering.
  • Represented Sera Prognostics, Inc. in its $19.3 million Series A financing led by Interwest Partners, Domain Partners, Catalyst Health Ventures, Osage University Partners, and UpStart Life Sciences Capital.